权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Credentialing next-generation human glioma models for precision therapeutics

认证下一代人类神经胶质瘤模型的精准治疗

基本信息

批准号：
10375043
负责人：
Frank Furnari
金额：
$ 61.85万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-01-12 至 2026-12-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10375043
关键词：
Address Affect Alabama Biological Biological Models Biology Blood - brain barrier anatomy Brain Brain Neoplasms CDKN2A gene Cells Chemicals Clinic Clinical Clustered Regularly Interspaced Short Palindromic Repeats Combined Modality Therapy Complex Coupled Credentialing Data Deletion Mutation Development Disease Drug Targeting Drug resistance Engineering Engraftment Ensure Epidermal Growth Factor Receptor Extracellular Domain Failure Foundations Future Generations Genetic Genetic Engineering Genetic Heterogeneity Genomics Genotype Glioblastoma Glioma Goals Growth Heterogeneity Human Human Pathology Inflammatory Investigational Therapies Malignant Neoplasms Malignant neoplasm of brain Malignant neoplasm of lung Mass Spectrum Analysis Methods Missense Mutation Modeling Molecular Molecular Conformation Molecular and Cellular Biology Mutation Operative Surgical Procedures Organoids PTEN gene Pathway interactions Patients Penetrance Pharmaceutical Preparations Pharmacotherapy Phenotype Phosphotransferases Play Pre-Clinical Model Precision therapeutics Preclinical Drug Development Primary Brain Neoplasms Proteomics Publishing Receptor Protein-Tyrosine Kinases Role Signal Transduction Symbiosis Testing Therapeutic Therapeutic Uses Tyrosine Kinase Inhibitor Universities Work Xenograft procedure base combat combinatorial design driver mutation drug sensitivity epidermal growth factor receptor VIII epigenomics established cell line experience experimental study genome editing human disease human model induced pluripotent stem cell inhibitor inhibitor therapy mouse model mutant neoplastic cell nerve stem cell neuro-oncology next generation next generation sequencing novel overexpression patient derived xenograft model preclinical development preservation resistance mechanism response small molecule success transcriptomics tumor tumor heterogeneity tumorigenesis

项目摘要

ABSTRACT Despite notable success in EGFR-driven lung cancer, precision therapeutics have failed in EGFR-driven gliomas, the most common and deadly primary brain tumors. Reasons for failure of EGFR therapies in this clinical context include the lack of preclinical models that faithfully recapitulate the biology of EGFR-driven gliomas, including intra-tumor heterogeneity, drugs specifically designed to target invasive brain tumor cells located behind and intact blood-brain barrier (BBB), and adaptive drug resistance. Here we will develop and molecularly credential novel, EGFR-driven human glioma models for use in preclinical development of EGFR tyrosine kinase inhibitor (TKI)-based therapies. The foundation of the proposal comes from the Furnari Lab, who developed a novel platform (iGBM) for engineering glioma models using CRISPR genome editing and has established intra-tumor genetic heterogeneity as a symbiotic driver of tumorigenesis. The Miller Lab has extensive experience in small molecule experimental therapeutics using genetically engineered gliomas model and next-generation sequencing. He also used a novel chemical proteomics method, multiplex inhibitor beads coupled with mass spectrometry, to assess the glioma kinome en masse and showed that dynamic kinome reprogramming contributes to targeted drug resistance in glioma models. He is now at the University of Alabama at Birmingham, where local collaborators have extensive experience with biologically faithful human patient-derived xenograft (PDX) models. The O’Rourke Lab is a pioneer in development of sophisticated glioblastoma organoid (GBO) models that faithfully recapitulate the biology of molecularly and cellularly heterogeneous human tumors. In this Multi-PI project, we will combine our expertise to address the following Aims: (1) To develop novel genetically engineered human models driven by the most common EGFR extracellular domain mutations. We will then biologically and molecularly credential these models against genetically-matched PDX and GBO using genomics, epigenomics, transcriptomics, and kinome proteomics, and therapeutically challenge them using a panel of EGFR TKI, including one designed to specifically target invasive glioma cells behind the intact BBB. (2) To credential heterogeneous EGFR mutant iGBM models via biological, molecular, and EGFR TKI therapeutic profiling. We will thus develop human models with defined driver mutations that will be useful adjuncts to PDX/GBO for preclinical drug development. Models will be used to develop future rational combination therapies that combat drug resistance and enhance EGFR TKI efficacy. This work will therefore help realize the unmet need of precision therapeutics in neuro-oncology.

摘要尽管在EGFR驱动的肺癌上取得了显著的成功，但精准治疗在EGFR驱动的肺癌上却失败了胶质瘤是最常见和最致命的原发脑瘤。EGFR治疗在这方面失败的原因临床背景包括缺乏忠实地概括EGFR驱动的生物学的临床前模型胶质瘤，包括肿瘤内的异质性，专为侵袭性脑肿瘤细胞设计的药物位于血脑屏障(BBB)后方且完好，并具有适应性耐药。在这里，我们将发展和分子凭证新的、EGFR驱动的人脑胶质瘤模型用于临床前研究以EGFR酪氨酸激酶抑制剂(TKI)为基础的治疗。该提案的基础来自于 Furnari Lab，他开发了一个新的平台(IGBM)，用于使用CRISPR设计脑胶质瘤模型基因组编辑，并已建立了肿瘤内遗传异质性作为共生驱动因素肿瘤发生学。米勒实验室在小分子实验疗法方面拥有丰富的经验基因工程胶质瘤模型和下一代测序。他还使用了一种新的化学物质蛋白质组学方法--多重抑制物微球与质谱仪联用--评估脑胶质瘤并表明动态的动态组重新编程有助于靶向耐药在神经胶质瘤模型中。他现在在阿拉巴马大学伯明翰分校，当地的合作者在那里在生物学上忠实的人类患者来源的异种移植(PDX)模型方面有丰富的经验。这个 O‘Rourke实验室是开发复杂的胶质母细胞瘤器质性(GBO)模型的先驱，该模型忠实地概括了分子和细胞异质性人类肿瘤的生物学。在此多PI中在这个项目中，我们将结合我们的专业知识来解决以下目标：(1)开发新的基因由最常见的EGFR胞外区突变驱动的工程化人类模型。到时候我们会的从生物学和分子水平上证明这些模型可以对抗基因匹配的PDX和GBO 基因组学、表观基因组学、转录组学和动态组蛋白质组学，并使用一组EGFR TKI，包括一个专门针对完整背后的侵袭性胶质瘤细胞的小组 BBB。(2)通过生物学、分子和EGFR验证异种EGFR突变型IGBM模型 TKI治疗性侧写。因此，我们将开发具有定义的驱动程序突变的人类模型，这将是 PDX/GBO的有用辅助药物用于临床前药物开发。模式将被用来发展未来合理的联合治疗，对抗耐药，提高EGFR TKI疗效。这项工作将因此，有助于实现神经肿瘤学中尚未满足的精确治疗需求。